Memorial Sloan Kettering CAR-T Cancer Immunotherapy Patent Application
Summary
Memorial Sloan Kettering Cancer Center filed US Patent Application US20260109675A1 on April 23, 2026, covering compositions and methods for adoptive cell therapy using engineered immune cells expressing a tumor antigen-targeted chimeric antigen receptor (CAR) and a prodrug converting enzyme. The application, filed as application number 19204167 with a priority date of May 9, 2025, names David A. Scheinberg, Thomas J. Gardner, Derek S. Tan, and Jonghan Lee as inventors. This A1 publication makes the patent application publicly available and establishes a priority date for the CAR-T immunotherapy technology.
“Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 256 changes logged to date.
What changed
USPTO published patent application US20260109675A1 for Memorial Sloan Kettering Cancer Center's CAR-T cancer immunotherapy technology. The application covers engineered immune cells expressing tumor antigen-targeted chimeric antigen receptors combined with prodrug converting enzymes for adoptive cell therapy. Named inventors include David A. Scheinberg, Thomas J. Gardner, Derek S. Tan, and Jonghan Lee, with application number 19204167 and filing date May 9, 2025.
For biotechnology and pharmaceutical companies developing cell therapies, this patent application establishes priority rights for a dual-function CAR-T approach combining antigen targeting with enzyme-based prodrug activation. Companies working on similar cell therapy platforms should review this application to assess potential freedom-to-operate implications and consider their own patent strategies around combination immunotherapy approaches.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER
Application US20260109675A1 Kind: A1 Apr 23, 2026
Assignee
MEMORIAL SLOAN KETTERING CANCER CENTER
Inventors
David A. SCHEINBERG, Thomas J. GARDNER, Derek S. TAN, Jonghan LEE
Abstract
Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.
CPC Classifications
C07D 239/94 A61K 35/17 A61K 40/11 A61K 40/31 A61K 40/4211 A61K 40/4243 A61K 40/427 C07C 235/34 C07H 19/16 C07K 14/7051 C07K 14/70517 C12N 5/0634 C12N 5/0636 C12N 9/485 C12Y 304/17011 A61K 2239/31 A61K 2239/38 A61K 2239/48 A61K 2239/49 A61K 2239/50 A61K 2239/59 C07K 2319/03 C07K 2319/30
Filing Date
2025-05-09
Application No.
19204167
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.